News & Updates

Aspirin for CRC prevention works better in presence of less healthy lifestyles

People with less healthy lifestyles appear to obtain greater protection against colorectal cancer (CRC) with aspirin use, according to a study.

Targeting PV source with ropeginterferon alfa-2b revolutionizes treatment

Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by overproduction of red blood cells, which poses a significant risk of thrombohaemorrhagic complications and impaired survival. Traditionally, treatment approaches have focused on managing the symptoms and reducing haematocrit levels, but these do not address the underlying cause of the disease.

Ropeginterferon alfa-2b (BESREMi, PharmaEssentia), an innovative monopegylated long-acting interferon, offers a novel approach by directly targeting and depleting JAK2-mutated hematopoietic stem cells (HSCs) in the bone marrow, which is the source of the disease. This article focuses on the role of ropeginterferon alfa-2b in transforming the treatment landscape for PV, its mechanisms, clinical benefits, and potential to significantly improve patient outcomes.

Female AYA cancer survivors: Are they at risk for adverse obstetric outcomes?

Female adolescent and young adult (AYA) survivors of certain types of cancer appear to be at risk of birth rate deficits and obstetric complications, suggests a retrospective study from the UK.

Celiac plexus radiosurgery may ease retroperitoneal pain syndrome

Ablative radiation delivered to the celiac plexus appears to reduce retroperitoneal pain syndrome in patients with cancer, according to a phase II study.

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

Bintrafusp alfa, an investigational first-in-class bifunctional fusion protein, appears to induce response in patients with recurrent or metastatic cervical cancer, according to a phase II study.